Novel development strategies and challenges for anti-Her2 antibody-drug conjugates

Antibody-drug conjugates (ADCs) combining potent cytotoxicity of small-molecule drugs with the selectivity and excellent pharmacokinetic profile of monoclonal antibody (mAb) are promising therapeutic modalities for a diverse range of cancers. Owing to overexpression in a wide range of tumors, human...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Xinling, Huang, Andrew C, Chen, Fahai, Chen, Hu, Li, Lele, Kong, Nana, Luo, Wenting, Fang, Jianmin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8826051/
https://www.ncbi.nlm.nih.gov/pubmed/35146330
http://dx.doi.org/10.1093/abt/tbac001

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8826051/
https://www.ncbi.nlm.nih.gov/pubmed/35146330
http://dx.doi.org/10.1093/abt/tbac001

Ejemplares similares